Toronto, Ontario–(Newsfile Corp. – February 11, 2022) – VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) (“VIVO” or the “Company“), a leading provider of medical cannabis products and patient services, and holder of licenses under the Cannabis Act through its wholly-owned subsidiaries, Canna Farms Limited (“Canna Farms”) and ABcann Medicinals Inc., today announced a partnership with Cicatrix Labs Ltd. (“Cicatrix Labs”) to offer Assuage™ vaginal and rectal suppositories on VIVO’s Canna Farms e-commerce marketplace.
“In keeping with our laser focused medical strategy, we are extremely proud to be the first legal medical marketplace in Canada to launch the broadest range of suppositories available to all Canadian patients,” commented Ray Laflamme, Canna Farms’ Co-Founder and VIVO’s Chief Executive Officer. “We’ve listened to our patients and advocacy groups, and we have recognized an unmet need for this specialized dosage format to support various women’s health conditions gastrointestinal health conditions affecting both men and women.”
Assuage™ suppositories for vaginal and rectal use are available in two formulations: 50 mg cannabidiol (CBD), and 1:3 formulation of 10 mg tetrahydrocannabinol (THC) and 30 mg CBD, with 8 suppositories per tin package.
“Assuage means to ‘ease, or make an unpleasant feeling less intense’, and these suppositories were designed keeping patient comfort and efficacy in mind for those unable to obtain relief with oral or inhaled cannabis,” commented Sarah Roberts, RPh, President and Founder of Cicatrix Labs. “Patients no longer have to purchase suppositories from the illegal market or make their own. Partnering with Canna Farms ensures broad access of this unique dosage format for tens of thousands of patients.”
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/113526
Powered by WPeMatico
